Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: (("mall" OR "all") or "half")
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
Search alternatives
:
"mall" »
"hall"
,
"fall"
,
"call"
Showing
1
-
6
of
6
Search:
'(("mall" OR "all") or "half")'
,
query time: 0.09s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Clinical review report: Lumacaftor/Ivacaftor (Orkambi) (Vertex Pharmaceuticals (Canada) Incorporated)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... CF-causing mutation worldwide and approximately
half
of
all
Canadian patients with CF are homozygous...
”
Read Now
2
Clinical review report: Lumacaftor/Ivacaftor (Orkambi) (Vertex Pharmaceuticals (Canada) Incorporated)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... CF-causing mutation worldwide and approximately
half
of
all
Canadian patients with CF are homozygous...
”
Read Now
3
Somatropin (Genotropin) for subcutaneous injection : the treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed
Published 2014
CADTH
“
...Turner syndrome (TS) is characterized by the absence of
all
or part of a normal second sex...
”
Read Now
4
Direct-acting antivirals for chronic hepatitis C genotype 1 : project protocol
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... to inhibit viral replication in patients with chronic hepatitis C (CHC). Approximately
half
of patients...
”
Read Now
5
Direct-acting antivirals for chronic hepatitis C genotype 1 : project protocol
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... to inhibit viral replication in patients with chronic hepatitis C (CHC). Approximately
half
of patients...
”
Read Now
6
Pharmacoeconomic review report: Lumacaftor/Ivacaftor (Orkambi) (Vertex pharmaceuticals (Canada) Incorporated) : indication, for the treatment of cystic fibrosis in patients 6 years...
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
... common CF-causing mutation worldwide and approximately
half
of
all
Canadian patients with CF...
”
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Year of Publication
From:
To:
Classification
610 - Medicine & health
5
140 - Specific philosophical schools
1
330 - Economics
1
Language
English
6
Collection
National Center for Biotechnology Information
6
Author
Canadian Agency for Drugs and Technologies in Health
Recently Uploaded
Last Month
1
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&lookfor=%28%28%22mall%22+OR+%22all%22%29+or+%22half%22%29&type=AllFields
Send by Email
×
Loading...